Please login to the form below

Not currently logged in
Email:
Password:

Unlicensed sex drugs seized by MHRA

Enforcement officers from the UK's Medicines and Healthcare products Regulatory Agency seize nearly USD 709,263 worth of unlicensed medicines

Enforcement officers from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have seized nearly GBP 350,000 (USD 709,263) worth of unlicensed medicines.

The drugs were discovered on 1 August 2007 at a secure lock-up facility in Uxbridge, West London and included Kamagra tablets and sachets, Lovegra and Apcalis, which are manufactured in India, but are unlicensed and untested despite claiming to treat male impotence. Investigations are ongoing.

Danny Lee-Frost, MHRA's head of criminal operations, said: ìThe type of medicines we seized cannot be guaranteed to be acceptably safe because they have not gone through the correct licensing regulatory process. At best these medicines could be a waste of money, at worst they could be severely detrimental to your health.î

If an individual is convicted of offences under the Medicines Act 1968, they can be sentenced to a maximum of two years imprisonment and/ or an unlimited fine. Where appropriate the MHRA will use the Proceeds of Crime Act 2002 to determine whether or not benefits were accrued through criminal activity and will recoup illicit earnings if the individual is found guilty.

7th August 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...